Rare Diseases

Tetra, Shionogi sign USD 40 Million deal for Alzheimer’s disease and fragile X syndrome Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer’s disease and fragile X syndrome. Shionogi will give a USD 5 million upfront payment and USD 35 million in equity. This will let Tetra earn up to USD 120 million in development and commercial milestones. The USD 40 million will let Michigan-based Tetra to finish an ongoing phase 2 trial in fragile X and to start another phase 2 trial in early Alzheimer’s disease. Amgen remunerates USD 50 Million for preclinical bispecific of Molecular Partners  Amg...